Recruiting
OBSERVATIONAL
NCT06473259
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice
Interventions
Name:
Docetaxel
Type:
DRUG
Description:
6 courses of docetaxel 75 mg/sqm iv
Name:
Apalutamide Oral Tablet
Type:
DRUG
Description:
240 mg /daily orally
Name:
Enzalutamide Oral Tablet
Type:
DRUG
Description:
600 mg /daily orally
Name:
Abiraterone acetate tablets
Type:
DRUG
Description:
1000 mg /daily orally
Name:
Darolutamide Oral Tablet
Type:
DRUG
Description:
600 mg/daily orally
Name:
radiotherapy
Type:
RADIATION
Description:
radical radiotherapy on primary tumor
Name:
Triptorelin
Type:
DRUG
Description:
3,75 mg im/4 w
Primary Outcomes
Measure:
progression free survival
TimeFrame:
From date of treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
Description:
the projected rate over the time of patients without progressive disease
Trial Information
NCT ID
NCT06473259
Status
Recruiting
Study Type
OBSERVATIONAL
Sponsor
Santa Chiara Hospital
Last Updated
December 15, 2025